About IQVIA Holdings Inc
- Industry: Life Sciences Tools & Services
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://ir.iqvia.com/
Frequently Asked Questions
What is the 52-week range for IQV?
The 52-week high is $277.4 and the 52-week low is $154.5.
What is the P/E ratio for IQV?
The Price to Earnings (P/E) ratio is 31.20.
What is the dividend yield for IQV?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 21.95%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 8.10%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 5.90.
Analyst Recommendation Trends
Wall Street analyst consensus for IQV over the last few months:
Latest IQV News
Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity
IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.
'HHS launches project to speed up clinical trials' - Axios
https://www.axios.com/2026/09/30/hhs-clinical-trials-redesign
UBS Reinstates Buy on IQVIA Holdings, Announces $345 Price Target
UBS analyst Kevin Caliendo reinstates IQVIA Holdings (NYSE:IQV) with a Buy and announces $345 price target.
IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
RESEARCH TRIANGLE PARK, N.C., September 29, 2026--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2026 financial results before the market opens on Tuesday, October 27, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompany
RBC Capital Maintains Outperform on IQVIA Holdings, Raises Price Target to $319
RBC Capital analyst Ryan Halsted maintains IQVIA Holdings (NYSE:IQV) with a Outperform and raises the price target from $247 to $319.
Truist Securities Reiterates Buy on IQVIA Holdings, Raises Price Target to $329
Truist Securities analyst Jailendra Singh reiterates IQVIA Holdings (NYSE:IQV) with a Buy and raises the price target from $300 to $329.
Can Doximity Keep Shrinking Its Share Count Through Its AI Investment Year?
Doximity (DOCS), which calls itself the leading digital platform for U.S. medical professionals, has seen its stock fall steeply over the past year. Even after a rise over the past three months, the shares sit about 65% below their 52-week high. Management continued its repurchase program, allocating approximately $401 million over the latest twelve months. The test is whether it can keep that up through what it calls its AI investment year.
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Novo Nordisk A/Sâs 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.
IQVIA (NYSE:IQV) Nears Breakout With 10/10 Technical Strength and 9/10 Setup
IQVIA stock shows 10/10 technical strength and 9/10 setup quality, pointing to a controlled breakout base with a defined entry, exit, and risk.
Tracking William Nygren's Harris Associates Portfolio - Q2 2026 Update
Harris Associates' 13F portfolio rose to $75.42B in Q2 2026, with 30 core positions exceeding 1.25% each. Read more on the portfolio here.
IQVIA Holdings (IQV) Prices $2b Notes, Does The Stock Look Fairly Valued?
IQVIA Holdings (IQV) has just priced a US$2b senior notes offering due 2034, a sizable refinancing move that reshapes its debt stack and gives investors fresh information on the company’s funding costs and capital structure. Over the past year IQVIA Holdings has delivered a 42.3% total shareholder return, with the share price up 58.8% over the last 90 days and 6.9% over the past month. The recent 1.1% daily pullback to US$266.42 therefore looks more like a pause after strong momentum than a...
IQVIA (IQV) Stock Could Be Undervalued After Its 42% Run
IQVIA Holdings has delivered a strong share-price run recently, which naturally puts more focus on whether the cash it is expected to generate can support the current valuation. With the stock now trading in a different zone to where it sat a year ago, the question is how that move lines up with its underlying cash flows. The share price is up 42.3% over the past year, which puts real pressure on the cash flow story to justify where IQVIA sits today. The company has priced a US$2b senior...
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Oncology spending may hit $441B by 2029 as growth slows from genericsâsee 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.
Morgan Stanley Maintains Equal-Weight on IQVIA Holdings, Raises Price Target to $270
Morgan Stanley analyst Kallum Titchmarsh maintains IQVIA Holdings (NYSE:IQV) with a Equal-Weight and raises the price target from $240 to $270.
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.
A Strong Rebound Case of IQVIA Holdings (IQV)
Broyhill Asset Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index’s 15.1% and the MSCI ACWI Value Index’s 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The […]
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IQVIA Holdings Stock: Is IQV Outperforming the Health Care Sector?
IQVIA Holdings has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.
IQVIA Announces Pricing of Senior Notes
RESEARCH TRIANGLE PARK, N.C., September 09, 2026--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of $2,000,000,000 in aggregate principal amount of senior notes due 2034 (the "Notes"). The proceeds from the Notes offering will be used to redeem in full the Issuer’s Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer’s revolving credit facility and to pay fees an
IQVIA Announces Offering of Senior Notes
RESEARCH TRIANGLE PARK, N.C., September 09, 2026--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $2,000,000,000 through an offering of senior notes due 2034 (the "Notes").
IQVIA (IQV): Buy, Sell, or Hold Post Q2 Earnings?
The past six months have been a windfall for IQVIA’s shareholders. The company’s stock price has jumped 50%, hitting $267.77 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
1 Profitable Stock with Solid Fundamentals and 2 That Underwhelm
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Software Rebound Extends Moat Index Gains
The S&P 500 gained 2.72% and reached a record high in August, with energy leading the market as crude prices rose. Read more here.
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
RESEARCH TRIANGLE PARK, N.C., September 03, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster.
VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast
Veeva raises its fiscal 2027 outlook as Vault CRM adoption, R&D growth and Falcon AI momentum support expanding revenue and profitability.
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-02 | Berkshire James G. | -5,381 | $131.82 | $709,323 |
| 2026-09-02 | Berkshire James G. | -2,713 | $261.54 | $709,558 |
| 2026-09-02 | Berkshire James G. | -2,668 | $261.33 | $697,228 |
| 2026-09-02 | Berkshire James G. | +5,381 | $131.82 | $709,323 |
| 2026-08-03 | STAUB W RICHARD | -5,500 | $232.68 | $1,279,740 |
| 2026-07-31 | Patel Bhavik | -1,855 | $235.27 | $436,426 |
| 2026-07-29 | Sherbet Eric | -5,000 | $249.16 | $1,245,800 |
| 2026-07-29 | Cherofsky Keriann | -558 | $245.21 | $136,827 |
| 2026-07-29 | BOUSBIB ARI | -156,206 | $78.21 | $12,216,871 |
| 2026-07-29 | BOUSBIB ARI | -2,069 | $247 | $511,043 |
| 2026-07-29 | BOUSBIB ARI | -47,858 | $244.6 | $11,706,067 |
| 2026-07-29 | BOUSBIB ARI | -53,191 | $244.78 | $13,020,093 |
| 2026-07-29 | BOUSBIB ARI | -44,039 | $246.08 | $10,837,117 |
| 2026-07-29 | BOUSBIB ARI | -4,584 | $246.85 | $1,131,560 |
| 2026-07-29 | BOUSBIB ARI | -4,465 | $247.1 | $1,103,302 |
| 2026-07-29 | BOUSBIB ARI | +156,206 | $78.21 | $12,216,871 |
| 2026-07-14 | Wims Morris Leslie | +148 | $207.83 | $30,759 |
| 2026-07-14 | Fasano Jim | +195 | $207.83 | $40,527 |
| 2026-07-14 | GOGGINS COLLEEN A | +183 | $207.83 | $38,033 |
| 2026-07-14 | DANHAKL JOHN G | +160 | $207.83 | $33,253 |
| 2026-05-07 | Wims Morris Leslie | +171 | $178.64 | $30,547 |
| 2026-05-07 | Fasano Jim | +228 | $178.64 | $40,730 |
| 2026-05-07 | GOGGINS COLLEEN A | +214 | $178.64 | $38,229 |
| 2026-05-07 | DANHAKL JOHN G | +185 | $178.64 | $33,048 |
| 2026-04-23 | Stamps Sheila A | +1,571 | $160.68 | $252,428 |
| 2026-04-23 | Wims Morris Leslie | +1,571 | $160.68 | $252,428 |
| 2026-04-23 | Kaelin William G Jr | +1,571 | $160.68 | $252,428 |
| 2026-04-23 | LEONARD JOHN M | +1,571 | - | - |
| 2026-04-23 | Fasano Jim | +1,571 | $160.68 | $252,428 |
| 2026-04-23 | Burt Carol | +1,571 | - | - |
| 2026-04-23 | GOGGINS COLLEEN A | +1,571 | - | - |
| 2026-04-23 | DANHAKL JOHN G | +1,571 | - | - |
| 2026-02-13 | Haas Bernd | -20 | $166.94 | $3,339 |
| 2026-02-13 | Fedock Michael J. | -123 | $166.94 | $20,534 |
| 2026-02-09 | Sherbet Eric | +12,112 | - | - |
| 2026-02-09 | Patel Bhavik | +11,180 | - | - |
| 2026-02-09 | Haas Bernd | +11,180 | - | - |
| 2026-02-09 | Grenfell Alistair | +26,088 | - | - |
| 2026-02-09 | Fedock Michael J. | +18,634 | - | - |
| 2026-02-09 | Cherofsky Keriann | +2,795 | - | - |
| 2026-02-09 | Berkshire James G. | +11,180 | - | - |
| 2026-02-09 | Wims Morris Leslie | +159 | $192.67 | $30,635 |
| 2026-02-09 | Fasano Jim | +211 | $192.67 | $40,653 |
| 2026-02-09 | GOGGINS COLLEEN A | +198 | $192.67 | $38,149 |
| 2026-02-09 | BOUSBIB ARI | +78,264 | - | - |
| 2026-02-09 | STAUB W RICHARD | +26,088 | - | - |
| 2026-02-09 | DANHAKL JOHN G | +172 | $192.67 | $33,139 |
| 2026-02-08 | Haas Bernd | -440 | $187.49 | $82,496 |
| 2026-02-08 | Haas Bernd | +8,265 | - | - |
| 2026-02-08 | Grenfell Alistair | -5,545 | $187.49 | $1,039,632 |
| 2026-02-08 | Grenfell Alistair | +11,795 | - | - |
| 2026-02-08 | Fedock Michael J. | -2,420 | $187.49 | $453,726 |
| 2026-02-08 | Fedock Michael J. | +6,735 | - | - |
| 2026-02-08 | Patel Bhavik | -1,920 | $187.49 | $359,981 |
| 2026-02-08 | Patel Bhavik | +4,083 | - | - |
| 2026-02-08 | Sherbet Eric | -1,915 | $187.49 | $359,043 |
| 2026-02-08 | Sherbet Eric | +6,806 | - | - |
| 2026-02-08 | Cherofsky Keriann | -415 | $187.49 | $77,808 |
| 2026-02-08 | Cherofsky Keriann | +1,087 | - | - |
| 2026-02-08 | Bruehlman Ronald E | -6,801 | $187.49 | $1,275,119 |
| 2026-02-08 | Bruehlman Ronald E | +16,335 | - | - |
| 2026-02-08 | Berkshire James G. | -1,280 | $187.49 | $239,987 |
| 2026-02-08 | Berkshire James G. | +2,722 | - | - |
| 2026-02-08 | BOUSBIB ARI | -28,399 | $187.49 | $5,324,529 |
| 2026-02-08 | BOUSBIB ARI | +57,177 | - | - |
| 2026-02-08 | STAUB W RICHARD | -806 | $187.49 | $151,117 |
| 2026-02-08 | STAUB W RICHARD | +2,722 | - | - |
| 2026-02-07 | Fedock Michael J. | -111 | $187.49 | $20,811 |
| 2026-01-28 | Fedock Michael J. | -381 | $239.76 | $91,349 |
| 2025-12-18 | BOUSBIB ARI | -50,000 | $59.9 | $2,995,000 |
| 2025-12-18 | BOUSBIB ARI | -13,436 | $222.91 | $2,995,019 |
| 2025-12-18 | BOUSBIB ARI | -36,564 | $222.43 | $8,132,931 |
| 2025-12-18 | BOUSBIB ARI | +50,000 | $59.9 | $2,995,000 |
| 2025-11-05 | Wims Morris Leslie | +146 | $210.12 | $30,678 |
| 2025-11-05 | Fasano Jim | +193 | $210.12 | $40,553 |
| 2025-11-05 | GOGGINS COLLEEN A | +181 | $210.12 | $38,032 |
| 2025-11-05 | DANHAKL JOHN G | +158 | $210.12 | $33,199 |
| 2025-10-29 | Sherbet Eric | -10,000 | $131.82 | $1,318,200 |
| 2025-10-29 | Sherbet Eric | -6,000 | $219.72 | $1,318,320 |
| 2025-10-29 | Sherbet Eric | -4,000 | $219.7 | $878,800 |
| 2025-10-29 | Sherbet Eric | +10,000 | $131.82 | $1,318,200 |
| 2025-10-29 | BOUSBIB ARI | -77,592 | $59.9 | $4,647,761 |
| 2025-10-29 | BOUSBIB ARI | -21,035 | $220.96 | $4,647,894 |
| 2025-10-29 | BOUSBIB ARI | -3,973 | $221.97 | $881,887 |
| 2025-10-29 | BOUSBIB ARI | -26,128 | $221.31 | $5,782,388 |
| 2025-10-29 | BOUSBIB ARI | -4,600 | $220.11 | $1,012,506 |
| 2025-10-29 | BOUSBIB ARI | -13,741 | $219.29 | $3,013,264 |
| 2025-10-29 | BOUSBIB ARI | -7,315 | $218.32 | $1,597,011 |
| 2025-10-29 | BOUSBIB ARI | -800 | $217.58 | $174,064 |
| 2025-10-29 | BOUSBIB ARI | +77,592 | $59.9 | $4,647,761 |